Genmab A/S (GNMSF) EBT (2018 - 2026)
Genmab A's (GNMSF) quarterly EBT came in at -$106.0 million in Q1 2026, down 143.44% YoY from $244.0 million in Q1 2025, and down 109.23% on a QoQ basis from $1.1 billion in Q3 2025.
Genmab A/S (GNMSF) EBT (2018 - 2026) Analysis & Trends
Genmab A (GNMSF) has 6 years of EBT data on file, last reported at -$106.0 million in Q1 2026.
- Quarterly EBT fell 143.44% year-over-year to -$106.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.0 billion (up 5.17% YoY) and the FY2025 annual result came in at $1.2 billion, down 9.2% from the prior year.
- EBT retreated to -$106.0 million in Q1 2026, from $1.1 billion in the prior quarter.
- In the past five years, EBT ranged from a high of $1.1 billion in Q3 2025 to a low of -$106.0 million in Q1 2026.
- A 3-year average of $509.7 million and a median of $556.0 million in 2024 frame the typical range for EBT.
- Annual changes were most pronounced in 2025 — EBT jumped 42.03% — and 2026, when it plunged 143.44%.
- Tracing GNMSF's EBT over 3 years: stood at $809.0 million in 2024, then soared by 42.03% to $1.1 billion in 2025, then sank by 109.23% to -$106.0 million in 2026.
- The last three EBT figures came in at -$106.0 million (Q1 2026), $1.1 billion (Q3 2025), and $667.0 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 295.00 Mn |
| Mar 31, 2026 | -106.00 Mn |
| Sep 30, 2025 | 1.15 Bn |
| Jun 30, 2025 | 667.00 Mn |
| Mar 31, 2025 | 244.00 Mn |
| Sep 30, 2024 | 809.00 Mn |
| Jun 30, 2024 | 556.00 Mn |
| Mar 31, 2024 | 249.00 Mn |
| Sep 30, 2020 | 671.00 |
| Dec 31, 2019 | 699.00 |
| Sep 30, 2019 | 699.28 Mn |
| Dec 31, 2018 | 230.60 Mn |